BR112018009879A2 - biomarcador da doença renal policística e seus usos - Google Patents

biomarcador da doença renal policística e seus usos

Info

Publication number
BR112018009879A2
BR112018009879A2 BR112018009879A BR112018009879A BR112018009879A2 BR 112018009879 A2 BR112018009879 A2 BR 112018009879A2 BR 112018009879 A BR112018009879 A BR 112018009879A BR 112018009879 A BR112018009879 A BR 112018009879A BR 112018009879 A2 BR112018009879 A2 BR 112018009879A2
Authority
BR
Brazil
Prior art keywords
pkd
patient
kidney disease
polycystic kidney
biomarker
Prior art date
Application number
BR112018009879A
Other languages
English (en)
Inventor
Bukanov Nikolai
Moreno Sarah
E Weeden Timothy
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BR112018009879A2 publication Critical patent/BR112018009879A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

são aqui fornecidos métodos para determinar a eficácia do tratamento da doença renal policística (pkd) em um paciente, diagnosticar a pkd em um paciente, graduar a pkd em um paciente e monitorar a pkd em um paciente. esses métodos incluem determinar um único ou múltiplos níveis de ambp. também são fornecidos kits que incluem um anticorpo que se liga especificamente à proteína ambp e pelo menos um anticorpo que se liga especificamente a um marcador adicional de pkd.
BR112018009879A 2015-11-18 2016-11-15 biomarcador da doença renal policística e seus usos BR112018009879A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562257089P 2015-11-18 2015-11-18
PCT/US2016/062075 WO2017087409A1 (en) 2015-11-18 2016-11-15 Biomarker of polycystic kidney disease and uses thereof

Publications (1)

Publication Number Publication Date
BR112018009879A2 true BR112018009879A2 (pt) 2018-11-13

Family

ID=57539614

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018009879A BR112018009879A2 (pt) 2015-11-18 2016-11-15 biomarcador da doença renal policística e seus usos

Country Status (12)

Country Link
US (2) US11116755B2 (pt)
EP (1) EP3377908B1 (pt)
JP (1) JP6895963B2 (pt)
KR (1) KR20180083902A (pt)
CN (1) CN108700594B (pt)
AU (1) AU2016357720A1 (pt)
BR (1) BR112018009879A2 (pt)
CO (1) CO2018006126A2 (pt)
EA (1) EA201891170A1 (pt)
MX (1) MX2018006250A (pt)
WO (1) WO2017087409A1 (pt)
ZA (1) ZA201803035B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201891170A1 (ru) 2015-11-18 2018-11-30 Джензим Корпорейшн Биомаркер поликистозной болезни почек и варианты его применения
PL3920912T3 (pl) 2019-02-04 2025-11-12 Genzyme Corporation Leczenie ciliopatii przy użyciu inhibitorów syntazy glukozyloceramidowej (gcs)
KR102859441B1 (ko) * 2019-11-22 2025-09-12 서울대학교산학협력단 Opn 검출용 제제를 포함하는, 다낭신의 진단용 조성물 및 이의 이용
JPWO2023145898A1 (pt) * 2022-01-27 2023-08-03

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710227B1 (en) 1998-09-16 2004-03-23 Cropdesign N.V. Cyclin-dependent kinase inhibitors and uses thereof
US6703395B2 (en) 1998-03-04 2004-03-09 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
US20040006074A1 (en) 1998-04-28 2004-01-08 The Government Of The United States Of America Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer
CA2256121A1 (en) 1998-06-08 1999-12-08 Hong Wang Cyclin-dependent kinase inhibitors as plant growth regulators
CA2335115C (en) 1998-06-16 2009-01-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Fused azepinone cyclin dependent kinase inhibitors
US6559152B2 (en) 1998-10-13 2003-05-06 Dupont Pharmaceuticals Company 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
DE60039601D1 (de) 1999-05-24 2008-09-04 Avi Biopharma Inc Antisense gegen c-myc zur behandlung von polyzystischer nierenkrankheit
US20040048844A1 (en) 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
US6593356B2 (en) 1999-10-20 2003-07-15 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
DE60108626T2 (de) 2000-04-25 2005-12-22 Bristol-Myers Squibb Co. Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
WO2002022133A1 (en) 2000-09-12 2002-03-21 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
CA2432417A1 (fr) 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R .A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
GB0101686D0 (en) 2001-01-23 2001-03-07 Cancer Res Campaign Tech Cyclin dependent kinase inhibitors
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
AU2002365211A1 (en) 2001-07-10 2003-09-02 Bristol-Myers Squibb Pharma Company 6-substituted pyrazolo (3,4-d) pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
GB0218625D0 (en) 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
TW200412966A (en) 2002-09-04 2004-08-01 Schering Corp Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004026229A2 (en) 2002-09-04 2004-04-01 Schering Corporation Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7074924B2 (en) 2002-09-04 2006-07-11 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004022559A1 (en) 2002-09-04 2004-03-18 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
MXPA05003058A (es) 2002-09-19 2005-05-27 Schering Corp Nuevas imidazopiridinas como inhibidores de cinasa dependientes de ciclina.
AU2003270846B2 (en) 2002-09-19 2006-11-23 Merck Sharp & Dohme Corp. Pyrazolopyridines as cyclin dependent kinase inhibitors
US7576085B2 (en) 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
NZ538686A (en) 2002-09-23 2008-01-31 Schering Corp Novel imidazopyrazines as cyclin dependent kinase inhibitors
EP1543008B1 (en) 2002-09-23 2007-11-07 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
GB0313677D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
WO2006012394A1 (en) 2004-07-21 2006-02-02 Tulane University Health Sciences Center Treatment of renal dysfunction and multiple myeloma using pacap compounds
EP1808694A1 (en) 2006-01-17 2007-07-18 Universitätsklinikum Freiburg Method for diagnosing polycystic kidney disease
EP2594563B1 (en) 2007-05-31 2018-07-18 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
US20100184110A1 (en) 2007-06-06 2010-07-22 Siemens Healthcare Diagnostics Inc. Predictive diagnostics for kidney disease
JP2011529500A (ja) 2008-07-28 2011-12-08 ジェンザイム コーポレーション 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害
CA2738768C (en) 2008-10-03 2017-10-31 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
WO2010141862A2 (en) 2009-06-05 2010-12-09 Mayo Foundation For Medical Education And Research Methods and materials for isolating exosomes
CN102858985A (zh) * 2009-07-24 2013-01-02 西格马-奥尔德里奇有限责任公司 基因组编辑方法
CN102018702B (zh) 2009-09-16 2012-07-18 北京大学 银杏内酯b的一种用途
ES2586947T3 (es) 2009-11-27 2016-10-19 Genzyme Corporation Genz 112638 para tratar la enfermedad de Gaucher o de Fabry en terapia de combinación
WO2011084548A2 (en) 2009-12-15 2011-07-14 King Faisal Specialist Hospital & Research Centre Methods and compositions for detecting recesssive familial fsgs and uses thereof
WO2012042061A1 (en) 2010-10-01 2012-04-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the progression and treating a chronic kidney disease in a patient
US20130276513A1 (en) * 2010-10-14 2013-10-24 The Regents Of The University Of California Methods for diagnosing and assessing kidney disease
JP6021021B2 (ja) 2010-11-05 2016-11-02 国立大学法人京都大学 多発性嚢胞腎の検査方法および治療剤のスクリーニング方法
JP2015527870A (ja) 2011-10-03 2015-09-24 セルマティックス， インコーポレイテッド 推定出生児が状態を発症する危険性を評価するための方法およびデバイス
US8961959B2 (en) 2011-10-17 2015-02-24 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
CN102590491B (zh) 2012-02-06 2014-12-10 中国人民解放军第三军医大学第一附属医院 一种用于早期筛查或辅助诊断泌尿系统疾病的检测试剂盒、检测方法及其用途
ES2982997T3 (es) 2012-07-03 2024-10-21 Fond Centro San Raffaele 2-desoxiglucosa para uso en el tratamiento de la enfermedad renal poliquística dominante autosomal o enfermedad hepática poliquística
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
CN106716136B (zh) 2014-08-04 2020-06-23 建新公司 多囊性肾病的生物标志物及其用途
EA201891170A1 (ru) 2015-11-18 2018-11-30 Джензим Корпорейшн Биомаркер поликистозной болезни почек и варианты его применения

Also Published As

Publication number Publication date
CO2018006126A2 (es) 2018-07-10
EA201891170A1 (ru) 2018-11-30
JP2019502902A (ja) 2019-01-31
US20210379031A1 (en) 2021-12-09
JP6895963B2 (ja) 2021-06-30
CN108700594B (zh) 2021-06-29
MX2018006250A (es) 2018-09-05
EP3377908B1 (en) 2020-08-05
US11116755B2 (en) 2021-09-14
WO2017087409A1 (en) 2017-05-26
US12150938B2 (en) 2024-11-26
CN108700594A (zh) 2018-10-23
US20180338961A1 (en) 2018-11-29
ZA201803035B (en) 2019-02-27
EP3377908A1 (en) 2018-09-26
KR20180083902A (ko) 2018-07-23
AU2016357720A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
BR112014031365A2 (pt) métodos de detectar doenças ou condições
BR112019005167A2 (pt) método e kit para analisar uma amostra
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
BR112018008799A2 (pt) método de prognóstico
MX387936B (es) Metodo para la cuantificacion de huevos de parasitos en las heces.
CR20170133A (es) Análisis de coagulación universal microfluídico basado en chips
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
BR112018010673A8 (pt) moléculas de anticorpo para april e seus usos
MX374652B (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco.
EP3839510A3 (en) Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
EA201791578A1 (ru) Панель биомаркеров для обнаружения рака
BR112016006312A2 (pt) método e kit para determinar a presença ou ausência de staphylococcus aureus resistente à meticilina em uma amostra biológica
BR112016029521A2 (pt) ?kit, dispositivo e método para a detecção de câncer de estômago?
BR112016002845A2 (pt) composições e métodos para tratar condições associadas ao complemento
BR112018009879A2 (pt) biomarcador da doença renal policística e seus usos
CO2019002608A2 (es) Biomarcadores de arn para angioedema hereditario
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
BR112017021507A2 (pt) métodos para a seleção de inibidores seletivos e não seletivos de fosfatase
EA201991506A1 (ru) Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов
SA518391028B1 (ar) Cd37 أجسام مضادة واختبارات للكشف عن
CL2019003485A1 (es) Métodos para redicur la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. (divisional solicitud 201900909)
MX2019006332A (es) Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal.
BR112019009765A2 (pt) anticorpo de ligação à anidrase carbônica e uso do mesmo
MX2018002354A (es) Métodos para el tratamiento de una enfermedad poliquística renal.
MX2019000591A (es) Tira mejorada de ensayo de analisis de orina de bajo volumen de muestra, kits analiticos y metodos de uso relacionados con la misma.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]